Rome V Pediatric Upper Gastrointestinal Disorders: Gastroenterology | May 2026

Rome V substantially expands pediatric upper gastrointestinal disorders of gut–brain interaction (DGBI), moving beyond the narrower Rome IV framework to include pediatric esophageal pain disorders, esophageal air-transit disorders, functional pediatric feeding disorders (FPFD), rumination syndrome, cyclic vomiting syndrome (CVS), chronic nausea syndrome (CNS), and functional dyspepsia (FD). The most important conceptual advance is that Rome V aligns pediatric DGBI with contemporary physiology—especially pH-impedance testing, high-resolution impedance manometry (HRIM), and structured multidisciplinary phenotyping—making diagnosis more mechanistically grounded and therapeutically actionable.

The overarching clinical shift is similar to adult Rome V: pediatric upper GI DGBI are no longer framed as vague symptom syndromes diagnosed only after exclusion, but as positive, physiology-supported disorders of gut–brain interaction. This is especially important in pediatrics, where symptom reporting is developmentally constrained and behavioral, sensory, autonomic, and feeding-related phenotypes often overlap. Rome V therefore formalizes a much more multidisciplinary model involving gastroenterology, psychology, nutrition, speech/swallow therapy, and behavioral medicine.

1. Pediatric Esophageal DGBI: A Major Reclassification Beyond “GERD”

One of the most practice-changing updates in Rome V is the formal separation of pediatric esophageal symptoms previously grouped under presumed GERD into three distinct physiologic phenotypes:

Reflux hypersensitivity (RH)

Reflux-negative esophageal pain disorder (RNEPD) (pediatric analog of adult functional heartburn)

Disorders of esophageal air-transit (aerophagia syndrome and supragastric belching)

This is a major clinical advance because many children previously labeled as refractory GERD are now more accurately classified into esophageal DGBI phenotypes using endoscopy plus pH-impedance testing, allowing more rational treatment and avoiding unnecessary prolonged acid suppression.

Reflux Hypersensitivity (RH)

Rome V defines pediatric RH as reflux-related pain symptoms with:

normal endoscopy,

no eosinophilic esophagitis (EoE),

normal acid exposure,

but positive symptom association with acid or nonacid reflux on pH-impedance testing.

This is one of the most important pediatric esophageal additions because it formally acknowledges that symptoms may be reflux-triggered despite normal acid burden, shifting the focus from acid quantity to sensory hypersensitivity and reflux perception.

Clinical implications:

PPI response is not diagnostically reliable for RH.

Empiric PPI trials may still be used, but should be time-limited (≤8 weeks).

Failure to improve should prompt endoscopy + pH-impedance, not indefinite acid escalation.

Treatment emphasis shifts toward neuromodulation and CBT, rather than acid suppression alone.

This is a major practical change in pediatrics, where prolonged empiric PPI use has historically been common.

Reflux-Negative Esophageal Pain Disorder (RNEPD)

RNEPD is the pediatric equivalent of adult functional heartburn and refers to reflux-like pain symptoms with:

normal endoscopy,

no EoE,

normal acid exposure,

and no temporal symptom–reflux correlation on pH-impedance testing.

This is highly clinically relevant because it identifies children with esophageal pain not driven by reflux at all, despite symptom similarity to GERD.

The most important therapeutic implication is explicit:

Antireflux surgery is not indicated in RNEPD.

Repeated escalation of acid suppression is generally inappropriate.

Management should prioritize neuromodulators + CBT, not procedural reflux therapy.

This is one of the most practice-protective statements in Rome V pediatric esophageal care.

2. Disorders of Esophageal Air-Transit: A New Pediatric Category

Rome V newly formalizes disorders of esophageal air-transit, enabled by advances in impedance and HRIM, which can distinguish directionality of air movement. This is an important pediatric innovation because belching and bloating syndromes have historically been poorly classified and often misdiagnosed as reflux or dyspepsia.

The new subtypes are:

Aerophagia syndrome

Supragastric belching (SGB) syndrome

Aerophagia Syndrome

Rome V redefines aerophagia as a syndrome only when excessive air swallowing causes clinically significant symptoms such as:

progressive daytime abdominal distention,

excessive belching,

flatulence,

bloating,

and quality-of-life impairment.

This is important because Rome V avoids overdiagnosing normal air swallowing as pathology. Testing is often unnecessary unless uncertainty exists; diagnosis is primarily clinical, with abdominal x-ray or impedance used selectively. Treatment is conservative and behavioral (speech therapy/CBT), with decompression reserved for severe cases.

Supragastric Belching (SGB)

SGB is now recognized as a distinct behavioral disorder characterized by repetitive esophageal air intake followed by immediate expulsion. This is a major conceptual advance because many children with repetitive “hiccups,” “belching,” or presumed reflux actually have behavioral air-transit disorders, not acid disease.

Rome V emphasizes:

SGB is usually diagnosable clinically,

often does not occur during sleep,

and is best treated behaviorally (breathing retraining, speech therapy, CBT), not pharmacologically.

3. Functional Pediatric Feeding Disorders (FPFD): One of the Most Important Rome V Additions

The most novel and clinically transformative pediatric addition in Rome V is the formal introduction of Functional Pediatric Feeding Disorders (FPFD). This is arguably the most important pediatric innovation in the entire Rome V upper GI framework.

Rome V introduces FPFD as a structured, physiology- and behavior-based alternative to the overly broad DSM-5 construct of ARFID, which the committee explicitly argues lacks sufficient granularity for GI practice. Rome V recommends replacing ARFID-like heterogeneity with more precise feeding phenotypes.

This is a major conceptual and practical advance because pediatric feeding problems are common, clinically heterogeneous, and often misclassified.

Rome V introduces four functional feeding phenotypes:

Hypersensitive dysphagia (HD)

Anticipatory restrictive feeding (ARF)

Hunger dysregulation feeding disorder

Medically triggered functional feeding disorder

Hypersensitive Dysphagia (HD)

HD is the pediatric analogue of adult functional dysphagia, but adapted for developmental limitations. Children perceive liquids/solids as passing abnormally despite:

normal mucosa,

normal structure,

no major motor disorder,

and normal bolus transit.

This is a clinically valuable distinction because it separates sensory dysphagia from structural and motor disease while accounting for the fact that children often cannot localize symptoms well.

Anticipatory Restrictive Feeding (ARF)

ARF describes children who restrict intake because they anticipate aversive eating-related symptoms such as:

pain,

nausea,

gagging,

choking,

bloating,

vomiting.

This is one of the most clinically useful new Rome V diagnoses because it identifies fear-based restrictive eating driven by symptom anticipation rather than structural dysfunction.

Hunger Dysregulation Feeding Disorder

Rome V introduces a novel hunger-axis disorder with:

reduced hunger drive, or

excessive hunger drive.

This is a uniquely pediatric and clinically important construct, especially for children with severe dysregulated intake patterns not explained by anatomy or classic eating disorders.

Medically Triggered Functional Feeding Disorder

This category recognizes children whose feeding dysfunction began during a medical illness (e.g., GERD, EoE) but persists after the medical condition has resolved, due to retained maladaptive feeding behaviors or sensory conditioning.

This is an especially important practical diagnosis in pediatric GI because it explains why children may remain functionally dysphagic or feeding-avoidant despite complete mucosal healing.

Why FPFD Matters Clinically

This entire section is one of the most practice-changing contributions of Rome V. It provides a far more clinically useful framework for children previously grouped vaguely under ARFID or “feeding difficulty,” and it strongly emphasizes:

structured multidisciplinary assessment,

routine screening for EoE and nutritional deficiencies,

behavioral and sensory phenotyping,

and targeted psychogastroenterology-based treatment.

4. Rumination Syndrome: Stronger Behavioral Framing

Rome V reframes pediatric rumination syndrome as a behavioral gut–brain disorder, not a reflux disorder. This is highly important clinically because rumination remains commonly mistaken for refractory GERD, gastroparesis, or vomiting disorders.

Rome V reinforces that:

diagnosis is usually clinical,

HRIM can confirm in atypical cases,

and diaphragmatic breathing is first-line therapy.

This stronger behavioral framing should substantially reduce unnecessary testing and procedural escalation.

5. CVS and Cannabinoid Hyperemesis: Better Modernization

Rome V updates pediatric CVS and formally incorporates cannabinoid hyperemesis syndrome (CHS) as a pediatric-relevant subgroup, reflecting increasing adolescent cannabis exposure.

This is clinically important because Rome V now explicitly requires:

chronic cannabis exposure,

stereotypical CVS-like vomiting,

and symptom resolution with sustained cannabis cessation

to diagnose CHS.

This improves diagnostic precision and helps avoid mislabeling adolescents with occasional cannabis exposure as CHS.

6. Chronic Nausea Syndrome (CNS): Formal Recognition of a Real Pediatric Syndrome

Rome V renames and formalizes chronic nausea syndrome, recognizing chronic nausea as a legitimate pediatric DGBI often linked to:

autonomic dysfunction,

POTS,

anxiety,

and functional comorbidity.

This is an important conceptual advance because chronic nausea has historically been under-recognized and often dismissed as nonspecific.

7. Functional Dyspepsia: Better Pediatric Alignment With Adult Rome V

Rome V updates pediatric FD to align more closely with adult criteria, particularly by:

formalizing PDS and EPS subtypes,

increasing required symptom frequency for PDS,

and refining postprandial symptom timing.

This improves diagnostic consistency across age groups and should improve trial design and phenotype-specific management.

Clinical Bottom Line

Rome V Pediatric Upper GI DGBI is a major advance because it moves pediatric neurogastroenterology from symptom-based empiricism to structured physiologic and behavioral phenotyping. The most important practice-changing advances are:

formal physiologic separation of pediatric esophageal pain syndromes from GERD,

introduction of air-transit disorders (aerophagia, SGB),

creation of functional pediatric feeding disorders (FPFD) as a major new diagnostic framework,

stronger behavioral reframing of rumination syndrome,

formal pediatric incorporation of CHS,

recognition of chronic nausea syndrome as a distinct disorder, and

better harmonization of pediatric FD with adult Rome criteria.

Among these, the single most important innovation is the introduction of FPFD, while the most immediately practice-changing esophageal update is the shift from empiric “refractory GERD” labeling to pH-impedance-based esophageal phenotyping. Collectively, Rome V makes pediatric upper GI DGBI substantially more precise, multidisciplinary, and clinically actionable.